DIBUCAINE OINTMENT

Dibucaine Ointment, USP, is a topical medication containing one percent dibucaine as the active ingredient, intended for rectal administration and external use only. It is supplied in a collapsible tube with a rectal applicator, packaged in units of one ounce or 28 grams, with a total shelf life of 36 months. At the time of receipt by the first government activity, the product must have a minimum of 31 months of remaining shelf life and must be stored at temperatures between 15°C and 30°C (59°F to 86°F). The labeling must include the National Stock Number, manufacturer details, date of manufacture, expiration or retest date, contract number, and lot number, and the packaging must comply with Medical Marking Standard No. 1, replacing all references to MIL-STD-129. The item is regulated by the FDA, and contractors must ensure compliance with all technical and quality requirements outlined in the DLA Master List of Technical and Quality Requirements. This procurement is governed by Contract SPE2DP-26-T-3069, with a delivery requirement of five days FOB destination, no tolerance for quantity variance, and inspection and acceptance occurring at the destination. The unit of issue is one pound (PG), equivalent to 28 grams, and the National Stock Number is 6505-00-299-9535. Packaging must meet MIL-STD-2073-1E standards, ensuring protection against damage and safe delivery via commercial carrier at the lowest cost. The manufacturer is The Harvard Drug Group, L.L.C., with NDC number 00536-1211-95, and all shipments must be marked in accordance with federal medical marking guidelines. The solicitation posted on April 26, 2026, requires responses by May 4, 2026, and is managed by the Department of Defense’s Medical Supply Chain PHARM FSA, with performance focused at Fort Stewart, Georgia.